The effect of biologicaly active substances on the structure and properties of collagenous substrates by Muchová, Johana
BRNO UNIVERSITY OF TECHNOLOGY
VYSOKÉ UČENÍ TECHNICKÉ V BRNĚ
FACULTY OF CHEMISTRY
FAKULTA CHEMICKÁ
INSTITUTE OF MATERIALS SCIENCE
ÚSTAV CHEMIE MATERIÁLŮ
THE EFFECT OF BIOLOGICALY ACTIVE SUBSTANCES ON
THE STRUCTURE AND PROPERTIES OF COLLAGENOUS
SUBSTRATES
VLIV BIOLOGICKY AKTIVNÍCH LÁTEK NA STRUKTURU A VLASTNOSTI KOLAGENOVÝCH SUBSTRÁTŮ
MASTER'S THESIS
DIPLOMOVÁ PRÁCE
AUTHOR
AUTOR PRÁCE
Bc. Johana Babrnáková
SUPERVISOR
VEDOUCÍ PRÁCE
doc. Ing. Lucy Vojtová, Ph.D.
BRNO 2016
Vysoké učení technické v Brně
Fakulta chemická
Purkyňova 464/118, 61200 Brno
Zadání diplomové práce
Číslo diplomové práce: FCH-DIP0914/2015 Akademický rok: 2015/2016
Ústav: Ústav chemie materiálů
Student(ka): Bc. Johana Babrnáková
Studijní program: Chemie, technologie a vlastnosti materiálů (N2820) 
Studijní obor: Chemie, technologie a vlastnosti materiálů (2808T016) 
Vedoucí práce doc. Ing. Lucy Vojtová, Ph.D.
Konzultanti:
Název diplomové práce:
Vliv biologicky aktivních látek na strukturu a vlastnosti kolagenových substrátů
Zadání diplomové práce:
1) Literární rešerše na téma porézní kolagenové substráty pro buňky a léčiva aplikované v tkáňovém
inženýrství
2) Příprava kolagenových substrátů s aditivy zvyšující jejich biologickou aktivitu
3) Chemicko-fyzikální charakterizace připravených vzorků
4) Biologická in-vitro charakterizace připravených substrátů
5) Porovnání výsledků, diskuze
6) Závěr
Termín odevzdání diplomové práce: 6.5.2016
Diplomová práce se odevzdává v děkanem stanoveném počtu exemplářů na sekretariát ústavu a v
elektronické formě vedoucímu diplomové práce. Toto zadání je přílohou diplomové práce.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Bc. Johana Babrnáková doc. Ing. Lucy Vojtová, Ph.D. prof. RNDr. Josef Jančář, CSc.
Student(ka) Vedoucí práce Ředitel ústavu
- - - - - - - - - - - - - - - - - - - - - - -
V Brně, dne 31.1.2016 prof. Ing. Martin Weiter, Ph.D.
Děkan fakulty
3 
 
ABSTRACT 
The thesis deals with the preparation of 3D porous collagen scaffolds by freeze-drying and 
their modification with bioactive compounds. The natural polysaccharides, chitosan, calcium 
oxidized cellulose and chitin/chitosan-glucan complex for the modification have been used. 
The mechanical properties of the scaffolds have been enhanced by crosslinking process 
with carbodiimides. Growth factors have been delivered in the form of platelet lysate. 
The influence of biologically active additives, crosslinking agents, and enrichment 
with growth factors on the properties of the prepared scaffold and their bioactivity in tissues 
of living organisms have been investigated. Specifically, this study includes 
the morphological properties, structure, porosity, swelling stability, chemical composition, 
temperature of denaturation and biological properties. Scanning electron microscopy, infrared 
specktroscopy, differential scanning calorimetry and confocal microscopy have been used 
to the characterization. 
Prepared collagen substrates involving bioactive additive and platelet lysate could be used 
as scaffold for growing cells in systems with low mechanical loading and which has potential 
application in biomedicine. 
 
ABSTRAKT 
Diplomová práce se zabývá přípravou 3D porézních kolagenových skafoldů metodou 
lyofilizace a jejich modifikací bioaktivními látkami. K modifikaci byly použity přírodní 
polysacharidy – chitosan, vápenatá oxidovaná celulóza a chitin/chitosan-glukanový komplex. 
Mechanické vlastnosti skafoldů byly upraveny síťováním pomocí karbodiimidů. Růstové 
faktory byly dodány formou destičkového lyzátu. 
Byl zkoumán vliv biologicky aktivních aditiv, siťovacího činidla a obohacení růstovými 
faktory na vlastnosti připravených skaffoldů a jejich bioaktivitu v tkáních živých organismů. 
Konkrétně byly studovány morfologické vlastnosti, struktura, porozita, botnání, stabilita, 
chemické složení, teplota denaturace a biologické vlastnosti. K charakterizaci byly použity 
metody rastrovací elektronová mikroskopie, infračervená spektroskopie, diferenční 
kompenzační kalorimetrie a konfokální mikroskop. 
Připravené kolagenové substráty obohaceny bioaktivním aditivem a destičkovým lyzátem 
mohou být využity v biomedicíně jako skafoldy pro růst buněk v systémech s nízkou 
mechanickou zátěží. 
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1 INTRODUCTION 
Collagen as a material for tissue engineering has long been studied for its unique biological 
and mechanical properties similar to the extracellular matrix. It is obtained from renewable 
sources which are physiologically intimate or almost identical to collagen in the human body. 
Creating a 3D porous structure, collagen may be used as a scaffold, which is able to substitute 
soft tissues. However, collagen has imperfections which can be eliminated by combination 
with other biomaterials. Many researches are aimed at modifying of collagen scaffolds using 
biodegradable polymers. Then the resulted scaffold exhibits suitable mechanical properties, 
stability and a certain biocompatibility required for regeneration of damaged tissue. 
The bioactivity is here the missing feature, which mediates the matrix interaction with live 
tissue and becomes indispensable component during regeneration of damaged tissues. 
By collagen scaffold modification using biologically active substances, the scaffold is able 
to provide not only supportive environment for cell growth of new tissue, but also accelerate 
the growth. Activity means the inclusion of additive substances into the metabolic processes 
of cells. Substances which were choosen to modify collagen scaffolds are oxidized cellulose, 
chitosan, and chitin/chitosan-glucan complex. These are polysaccharides that are derived from 
natural sources, they are biodegradable and exhibit biological activity. 
Complete tissue regeneration occurs as supplies of signals which initiate the healing 
process, the proliferation of cells and mediate communication between the scaffold and 
undamaged cells. Here it is necessary to use growth factors derived from autologous tissue, 
otherwise it may occur allergic reactions. An effective method has been proposed to use blood 
lysate due to high content of growth factors and ease of preparation. 
By combining the collagen, bioactive agents and growth factors, a proper scaffold is 
prepared. It can  replace the extracellular matrix and is a suitable environment for adhesion 
and proliferation of cells. The scaffold performs these functions for a period of recovery, 
which gradually degrades while forming new tissue structure. 
Comparing the results obtained from the prepared scaffolds, the use of scaffolds for tissue 
engineering and further adjustment will be able to better specify. 
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2 CURRENT STATE OF THE ART 
2.1 Regenerative Medicine 
Regenerative medicine is a broad interdisciplinary field defined by the goal 
of  reconstructing, repairing, or replacing missing or damaged tissue (cells, organs) to a state 
as close as possible to its native architecture and function. Goal should always be to restore 
the patients to a state of natural form and function through our surgical interventions [1]. 
In regenerative medicine, cell therapies are the major interest. The main aim of cell therapy 
is to replace the biological function of demaged tissue or organs. This can be achieved 
by the transplantation of isolated and characterized cells to a target organ in sufficient number 
and quality for them to survive long enough to restore function [2]. 
Development of technology to enable transplanted cells to be engrafted for a long time is 
indispensable for maximizing the effects of regenerative medicine. As a simple method 
appears the transplantation of cells as a single cell suspension, but many cells are known to be 
lost soon after transplantation, which leads to marginal effects. Tissue engineering is 
a promising strategy to overcome these problems [3]. 
2.2 Tissue Engineering 
Tissue engineering means the application of principles and methods of engineering and life 
sciences toward the fundamental understanding of structure-function relationships in normal 
and pathological mammalian tissues and the development of biological substitutes to restore, 
maintain or improve tissue function [4]. 
Tissue engineering combines the use of i) cells, ii) signals and iii) scaffolds for the purpose 
of tissue/organ repair/regeneration (Figure 1). 
i) The diversity of cell-based applications has dramatically increased with both 
somatic and stem cell populations being used for tissue engineering. They are being 
derived from sources throughout the body and our expanding knowledge of cell 
plasticity and fate has allowed for greater control over their behavior [5]. 
ii) Signals means biological factors, which are tissue-inducing substances and plays 
a critical role in organ morphogenesis and regeneration, and refer to a controlling 
cell behavior and direct tissue and organ repair [6]. 
iii) Engineered scaffolds primarily function as the extracellular matrix holding tissues 
together, but they have increasingly been used for cell and/or biomolecule delivery 
as well. 
Creating functional multi-tissue constructs is difficult, because generating manner through 
cell-cytokine-matrix interactions must be controlled over time and space.  
In the following will be discussed the combined use of cells, scaffolds, and inductive 
therapies for tissue engineering. 
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Figure 1: The triad of cell homing-based tissue engineering. To generate functional biohybrid 
prostheses from these substantial components, specific biologic signals provide desired phenotypes 
and behaviour of the cell [7]. 
2.3 Cells 
Cells constitute the fundamental unit of tissues and exhibit a broad spectrum of functional 
diversity. Two main categories of cellular components will be considered for use in tissue 
engineering: stem and progenitor cells and mature differentiated cells.  
Adult stem cell populations are found in almost every tissue and play a pivotal role 
in tissue homeostasis [8]. Adult stem cells have the capacity to restore and regenerate tissues 
and are already programmed to sustain a specific tissue type [9]. Differentiated adult cells 
perform discrete and highly specialized functions that define a particular tissue. They have 
the advantage of already being defined toward a specific lineage and do not require specific 
manipulation to perform a tissue-specific task. By contrast, they lack intrinsic regenerative 
potential and thus are potentially limited in their usefulness for tissue engineering. Anyway, 
paracrine communication between stem cells and differentiated cells is likely important 
to maintain the proper function of each subpopulation and these codependent interactions can 
potentially be augmented to enhance functional tissue engineering [5]. 
Stem cell is a cell with the ability for self-renewal and diferentiantion potential.  Self-
renewal means asymmetric cell division which leads to at least one daughter cell which is 
equal to mother cell [10].  Differentiation refers to the ability of a stem or progenitor cell 
to form a mature lineage cell.  
Progenitor cell is partially differentiated cell which can proliferate and has the capacity 
to differentiate but with no self-renewal ability. 
Potency is defined as the ability to differentiate into mature lineage cells and tissues [11].  
There are different stem cell types possess varying degrees of potency [10]: 
 Totipotent cells – form whole organism, e.g. zygote, a fertilized egg. 
 Pluripotent cells – form all germ layers i.e. ectoderm, mesoderm and endoderm, 
e. g. embryonic stem cells. 
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 Multipotent cells – form multiple cell lineages which create an entire tissue, usually 
specific to one germ layer, e.g. adult stem cells - hematopoietic stem cells (HSCs), 
mesenchymal stem cells (MSCs). 
 Oligopotent cells – form two or more cell lineages in a tissue, e. g. neuronal stem 
cells with ability to form different neurone types. 
 Unipotent cells – form one cell lineage, e.g. spermatogonial stem cells, intestinal 
crypt stem cells, follicular bulge skin stem cells. 
Plasticity refers to the controversial possibility for adult stem cells to show higher potency 
in response to different microenvironments. The niche is cellular microenvironment providing 
support and stimuli to control stem cell properties [10]. 
 
Figure 2: Schematic of different stem cell types divided by the potency and their differentiantion 
potential [12]. 
Other cell types used for tissue engineering include embrionic stem cells (ESCs) which can 
differentiate into tissues from all 3 germ layers but are complicated by the potential 
for tumorigenesis and ethical concerns [13]. The development of induced pluripotent stem 
(iPS) cell technology promises to provide tissue engineers with an entirely new set of tools 
to fabricate organs [14].  
In summary, a diverse population of cells critically maintains normal organ homeostasis 
and these cells and their interactions must be tightly regulated to successfully engineer 
functional tissue/organ constructs. 
2.4 Signals 
While a primary requirement of tissue engineering is to select the optimal cell types and 
scaffold properties to reconstruct a specific tissue in its particular configuration and function, 
a pivotal variable for succesful regeneration is the cellular microenvironment in which cells 
and tissue grow [15]. 
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Cell fate is influenced by a number of factors and interactions that require robust control 
for safe and effective regeneration of functional tissue. Coordinated interactions with cellular 
microenvironment that cells sense and that performs complex and dynamic regulation 
of cellular processes. The basis for tissue regeneration, therfore, is the utilization 
of engineering techniques that mimic the critical aspects of natural healing processes, 
„the wound healing cascade― by providing suitable biochemical and physico-chemical factors 
[16]. The self-healing capacity of patients can be augmented by artificially accelerating 
the proliferation and differentiation of the recruited or implanted cells via the integration 
of growth factors (GFs) and cytokines [16], [17]. It is indispensable to provide cells with 
a local biochemical and mechanical niche mimicking the natural environment in which they 
can proliferate and differentiate efficiently by creating an artificial extracellular matrix (ECM) 
and/or by delivering GFs [16], [17], [18], [19], [20], [21], [22]. One fundamental approach 
to tissue engineering has been to create such an environment to mimic the natural „wound 
healing cascade― for induction of regeneration and to accelerate/exploit the inherent capability 
for tissue regrowth that is generally termed regenerative medicine [16]. Within the complex 
cascade of biological events, GFs are known to play a central role in information transfer 
between a wide range of cells and their ECM, and stimulating endogenous repair mechanisms 
by providing the right signale to cells a thereby leading to an accelerated functional 
restoration of damaged or defective tissues [23], [24], [25], [26]. 
2.4.1 Platelet-Rich Plasma 
Platelet-rich plasma (PRP) is a platelet concentrate in a small volume of plasma that is 
typically developed from autologous blood [27]. Platelets are cytoplasmic fragments 
of megakaryocytes and play a central role in the complex process of hemostasis. Clot 
formation and platelet activation are considered the first steps of the healing proces [28]. 
Within 10 minutes of blood coagulation, platelets release a burst of proteins from their α, δ, 
and λ granules. These organelles contribute the numerous biologically active molecules that 
provide platelets with their healing properties. The contents of the -granule include many 
growth and differentiation factors that are released upon platelet activation during injury 
to the vessel wall [29]. The combined effects of these growth factors create an elaborate 
autocrine and paracrine process, and therefore may result in tissue-specific responses.  
Within an hour of activation, 95% of the granule‘s previously manufactured growth factors 
will be secreted. The platelets then sustain production of additional growth factors over 
the next several days [30]. 
For the platelets to release this cascade of molecules that contribute to tissue healing, they 
must first be activated. Some studies activate PRP with thrombin and or calcium [31].  Once 
activated, the resulting PRP mixture must be injected immediately, as the subsequent 
secretion of the granule contents occurs rapidly. The addition of thrombin and calcium 
to the platelet mixture produces a gel that cannot be injected even using a largegauge needle, 
thus limiting its use in certain surgical procedures. 
The application of soluble type-I collagen has been evaluated as an alternative to thrombin 
and calcium in platelet activation. Activation via type-I collagen produces a less rapid release 
of the granule contents, which enable a delayed administration of PRP. When compared with 
thrombin activation, the collagen-activated platelets produced equal concentrations 
of particular growth factors with less clot retraction. The collagen activation technique also 
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permits in vivo activation that can be administered through a small-gauge needle. These 
results suggest that type-I collagen may be an effective method for platelet activation [32]. 
2.4.1.1 Growth Factors in PRP 
Benefits of this therapy with PRP at the molecular level include the intrinsic properties 
of its growth factors. It is important to note that growth factors are not the only elements 
present in significant concentrations in PRP, as proteins of the cytokine and chemokine 
families are known to be present in varying concentrations as well. The elements identified 
in PRP include TGFβ, vascular endothelial growth factor (VEGF), platelet-derived 
endothelial growth factor, epidermal growth factor, insulin-like growth factor, platelet factor 
4, IL-1, platelet-derived angiogenesis factor, epithelial cell growth factor, osteocalcin, 
osteonectin, thrombospondin-1, fibrinogen, fibronectin, and vitronectin. The concentrations 
of these various growth factors increase linearly as platelet concentration increases [29], [33]. 
The network of activated growth factors induces intracellular signaling pathways that lead 
to the production of proteins essential to the regenerative processes, such as cell proliferation, 
matrix formation, osteoid production, and collagen synthesis [34]. 
Cell types that are involved in the healing process, such as osteoblasts, fibroblasts, 
epithelial cells, endothelial cells, and adult mesenchymal stem cells reveal the presence 
of membrane receptors that are specific for certain growth factors. Furthermore, when 
cytokines are released they bind to the transmembrane receptors on the surface of local or 
circulating cells [28], [35]. At the time of injury, the platelets arrive via the capillaries and are 
activated, releasing their granule contents into the wound site. This influx of growth factors 
and proteins play an active role in synthesizing the necessary components for the regenerative 
process and may also play a paracrine role by recruiting other cells to the wound site. 
A summary of these growth factors, their role in the healing proces are presented 
in Table 1. 
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Table 1: Effect of the growth factors produced by platelets [36]. 
Growth factor Effect 
PDGF  
(platelet-derived growth factor) 
Macrophage activation and angiogenesis 
Fibroblast chemotaxis and proliferative activity 
Enhances collagen synthesis 
Enhances the proliferation of bone cells 
TGF-β  
(transforming growth facor-β) 
Enhances the proliferative activity of fibroblasts 
Stimulates biosynthesis of type I collagen and fibronectin 
Induces deposition of bone matrix 
Inhibits osteoclast formation and bone resorption 
IGF-1 
(insulin-like growth factor-1) 
Chemotactic for fibroblasts and stimulates protein synthesis 
Enhances bone formation by proliferation and differentiation 
of osteoblasts 
PDEGF  
(platelet-derived endothelial growth 
factor) 
Promotes wound healing by stimulating the proliferation 
of keratinocytes 
and dermal fibroblasts 
PDAF  
(platelet-derived angiogenesis factor) 
Induces vascularization by stimulating vascular endothelial cells 
PF-4  
(platelet factor-4) 
Stimulates the initial influx of neutrophils into wounds 
A chemoattractant for fibroblasts 
A potent antiheparin agent 
EGF  
(endothelial growth factor) 
Cellular proliferation 
Differentiation of epithelial cells 
VEGF  
(vascular endothelial growth factor) 
Angiogenesis 
Migration and mitosis of endothelial cells 
Creation of blood vessel lumen 
Creates fenestrations 
Chemotactic for macrophages and granulocytes 
Vasodilation (indirectly by release of nitrous oxide) 
2.4.1.2 Preparation of Platelet-Rich Plasma 
The whole blood which is a mixture of cells, colloids and crystalloids can be separated into 
different blood components namely packed red blood cell (PRBC) concentrate, platelet 
concentrate, fresh frozen plasma and cryoprecipitate [27], [37]. 
In increasing order, the specific gravity of blood components is plasma, platelets, 
leucocytes (Buffy Coat [BC]) and packed red blood cells (PRBCs) [38]. 
The components are prepared by centrifugation of one unit of whole blood. Single 
component required can also be collected by apheresis procedure in blood donors. 
Different platelet concentrates can be classificated into four categories, depending on their 
leucocyte and fibrin content:  
 pure platelet-rich plasma (P-PRP), 
 leucocyte- and platelet-rich plasma (L-PRP), 
 pure plaletet-rich fibrin (P-PRF), 
 leucocyte and platelet-rich fibrin (L-PRF). 
 All available PRP techniques have some points in common: 
Blood is collected with anticoagulant just before or during surgery and is immediately 
processed by centrifugation. The time for platelet concentrate preparation is variable but is 
always completed within an hour. A first centrifugation step is designed to separate the blood 
into three layers, red blood cells (RBCs) are found at the bottom, acellular plasma (PPP, 
platelet-poor plasma) is in the supernatant and a ‗buffy coat‘ layer appears in between, 
in which platelets are concentrated (Figure 3). The next steps vary among the numerous 
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protocols but are an attempt to discard both the RBC layer and the PPP to collect only 
the ‗buffy coat‘ layer. Finally, the obtained platelet concentrate is applied to the surgical site 
with a syringe, together with thrombin and/or calcium chloride (or similar factors) to trigger 
platelet activation and fibrin polymerization. 
In Choukroun‘s PRF (platelet-rich fibrin) preparation is blood collected without any 
anticoagulant and immediately centrifuged. A natural coagulation process then occurs and 
allows for the easy collection of a leucocyte- and platelet-rich fibrin (L-PRF) clot, without 
the need for any biochemical modification of the blood, that is, no anticoagulants, thrombin 
or calcium chloride are required [39]. 
 
Figure 3: Classical manual platelet-rich plasma (PRP) protocol using a two-step centrifugation 
procedure [40]. 
2.4.1.3 Platelet Lysate 
Platelets constitute a potential source of multiple GFs and proteins involved in tissue 
regeneration. Some of GFs are available in purified form, but it has been pointed out that 
tissue repair cannot be effectively mediated by a single agent, as multiple signals are required 
to complete the regeneration process. Moreover it is also recognized that the efficacy 
of the GFs critically depends on the way they are made available to the injured tissue [41]. 
Platelet-rich preparations are hemoderivatives, from which platelets can release their 
complete pool of biologically active substances.Among these hemoderivatives is platelet-rich 
plasma (PRP), which can be obtained from the patient (autologous) or from donors (allogenic) 
[42], [43], [44], [45]. 
The platelet concentrate can therefore be activated by adding thrombin or calcium to form 
athree-dimensional and biocompatible fibrin scaffold (fibringlue). The term ‗releasate‘ is 
usually used to describe the preparations, which consist of bioactive molecules in a solution 
obtained by activation of platelets with calcium or thrombin, while the term ‗lysate‘ indicates 
the solution of bioactivemolecules obtained by platelet destruction by freeze-thawing,usually 
starting from a PRP sample in the presence of ananticoagulant agent [46].  
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Platelet lysate promotes keratinocyte epithelialization and regulates fibroblast matrix 
deposition, providing a molecular basis for the capability of such hemoderivative to heal 
severe and problematic wounds [47].  
Platelet lysate loaded in gel and sponge-like dressings intended for the treatment 
of mucosal, corneal and skin lesions. Such formulations were capable to enhance in vitro 
proliferation of fibroblasts and corneal (RCE) cells [48], [49], [50], [51], [52]. 
2.5 Scaffold 
Tissue engineering technologies are based on the biological triad and involve 
the successful interaction between three components: (1) the scaffold that holds the cells 
together to create the tissue‘s physical form; (2) the cells that create the tissue; and (3) 
the biological signalling molecules, such as growth factors, that direct the cells to express 
the desired tissue phenotype [53]. 
Scaffold is the central component that is used in tissue engineering to deliver cells, drugs, 
and genes into the body. They are most commonly recognized as defined structure 
biomaterials potentially able to perform useful functions: 
(i) promoting cell attachment, survival, proliferation and differentiation while 
possessing minimum toxicity in the original and biodegraded forms;  
(ii) allowing the transport or delivery of gases, nutrients and growth factors; 
(iii) offering sufficient structural support while being degradable at appropriate rates 
for tissue regeneration [54]. 
The scaffolds provide a three-dimensional structure for cell adhesion, proliferation, 
differentiation, and secretion of extracellular matrices to guide new tissue formation and 
regeneration [55]. These scaffolds essentially act as a template for tissue formation and are 
typically seeded with cells and occasionally growth factors, or subjected to biophysical 
stimuli in the form of a bioreactor; a device or system which applies different types 
of mechanical or chemical stimuli to cells [56].  
These cell-seeded scaffolds are either cultured in vitro to synthesize tissues which can then 
be implanted into an injured site, or are implanted directly into the injured site, using 
the body‘s own systems, where regeneration of tissues or organs is induced in vivo [1]. 
When cells are implanted or seeded into an artificial structure capable of supporting three-
dimensional (3D) tissue formation, these structures are called ―cell delivery scaffolds,‖ and 
when drugs are loaded into a 3D artificial porous structure capable of high drug loading 
efficiency and sustained release of a drug for longer duration, they are called ―drug delivery 
scaffolds‖ [57].  
Different forms of polymeric scaffolds for cell/drug delivery are available (Figure 4):  
(i) 3D porous matrix – a highly porous and well interconnected open pore structure 
that allows high cell seeding density and tissue in-growth; (ii) 
(ii) nanofibrous matrix – prepared by electrospinning or self-assembly would provide 
a better resemblance of the physiological environment [56], [58]; 
(iii) thermosensitive sol-gel transition hydrogel - physically or chemically cross-linked, 
water-soluble polymers, which swell to form a gel like substance on exposure 
to water [59]; 
(iv) porous microsphere and microparticles - delivering biomolecules such as growth 
factors, genes, and cells [60]. 
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Figure 4: Different forms of polymeric scaffolds for tissue engineering [61]. 
These are already widely utilized as sustained protein-release formulations and have been 
applied in tissue engineering for the potential use as a cell delivery carrier or supportive 
matrix [62], [63]. 
Of the polymeric scaffolds a typical 3D porous matrix and nanofibrous matrix are 
the implantable forms and a thermosensitive sol-gel transition hydrogel and porous 
microsphere are the injectable forms [64]. 
2.5.1 Properties of Scaffold Matrices 
An ideal tissue engineering scaffold (cell delivery) should fulfill the following 
requirements [65]: 
 mechanical properties that are sufficient to shield cells from tensile forces without 
inhibiting biomechanical cues, 
 desired volume, shape, and mechanical strength [58],  
 acceptable biokompatibility 
 a highly porous and well-interconnected open pore structure to allow high cell seeding 
density and tissue in-growth 
 bioadsorption at predetermined time period 
 biocompatible chemical compositions and their degradation products,  
 causingminimal immune or inflammatory responses [66],  
 physical structure to support cell adhesion and proliferation,  
 facilitating cell–cell contact and cell migration [64]. 
In the section below we will learn more about desired properties. 
Mechanical properties of the scaffold should match those of the tissue at the implantation 
site, or the mechanical properties at least should be sufficient to shield cells from damaging 
compressive or tensile forces without inhibiting appropriate biomechanical cues [64], [67] and 
to survive under physiological conditions [53]. 
Mimicking the native extracellular matrix (ECM), an endogenous substance that surrounds 
cells, allows them to bind into tissues and provide signals that aid cellular development and 
morphogenesis [64]. 
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The scaffold should possess relatively easy processability and malleability into the desired 
shape, according to the need. They should be capable of being produced into a sterile product. 
The scaffold should possess acceptable biocompatibility and toxicity profiles. Cells must 
adhere, function normally, and migrate onto the surface and eventually through the scaffold 
and begin to proliferate before laying down new matrix. After implantation, the scaffold must 
elicit a negligible immune reaction in order to prevent it causing such a severe inflammatory 
response that it might reduce healing or cause rejection by the body [1]. 
It should have a reproducible microscopic and macroscopic structure with a high surface: 
volume ratio suitable for cell/drug attachment [68]. Scaffolds should have an interconnected 
pore structure and high porosity to ensure cellular penetration and adequate diffusion 
of nutrients to cells within the construct and to the extra-cellular matrix formed by these cells. 
A porous interconnected structure is also required to allow diffusion of waste products out 
of the scaffold [1]. Cells primarily interact with scaffolds via chemical groups (ligands) 
on the material surface. Scaffolds synthesized from natural extracellular materials (e.g. 
collagen) naturally possess these ligands in the form of Arg-Gly-Asp (RGD) binding 
sequences, whereas scaffolds made from synthetic materials may require deliberate 
incorporation of these ligands through another mechanism, for example, protein adsorption. 
The ligand density is influenced by the specific surface area. This depends on the mean pore 
size in the scaffold. The pores thus need to be large enough to allow cells to migrate into 
the structure, but small enough to establish a sufficiently high specific surface, leading 
to a minimal ligand density to allow efficient binding of a critical number of cells 
to the scaffold [64]. 
The scaffold should have a maximum loading capacity so the drug is released continuously 
for longer duration after insertion into the body. The drug release from the scaffold needs 
to be controlled to allow the appropriate dose of drug to reach the cells over a given period 
of time. 
Binding affinity must be sufficiently low to allow release of the drug. 
They should posses dimensional stability, chemical stability, and biological activity over 
a prolonged period of time [57]. 
The scaffold material should be biodegradable, its degradation products should not be toxic 
and should be eliminated easily from the implantation site by the body [53], eliminating 
the need for further surgery to remove it [69]. The scaffold‘s degradation rate should be 
adjusted to match the rate of tissue regeneration so that it has disappeared completely once 
the tissue is repaired [68].  
The matrix material of the scaffold should be biodegrade at a controllable rate that 
approximates the rate of natural tissue regeneration and should provoke a minimal immune 
and/or inflammatory response in vivo [53]. Tissue engineering scaffolds are meant to be 
colonized by cells and should transmit the chemical and physical cues necessary to ensure 
adequate tissue growth. Synthetic polymer scaffolds may be used to deliver proteins and 
growth factors with or without cells locally to enhance tissue repair and regeneration [57]. 
2.6 Biomaterials for Scaffolds 
There are three individual groups of biomaterials: ceramics, synthetic polymers and natural 
polymers, in the fabrication of scaffolds for tissue engineering. 
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2.6.1 Natural Polymers 
Natural polymers often possess highly organized structures and may contain 
an extracellular substance, called ligand, which can be bound to cell receptors and thay 
exhibit biological activity and typically promote excellent cell adhesion and growth. they are 
also biodegradable and so allow host cells, over time, to produce their own extracellular 
matrix and replace the degraded scaffold [71]. However, as natural polymers can guide cells 
to grow at various stages of development, they may stimulate an immune response at the same 
time. This leads the concerns over antigenic and deliver of diseases for allograft [72]. 
Natural polymers include alginate, proteins, collagens, gelatin, fibrins, albumin, elsinan, 
pectin (pectinic acid), galactan, curdlan, gellan, levan, emulsan, dextran, pullulan, gluten, 
elastin, fibroin, hyarulonic acid, cellulose, starch, chitosan (chitin), scleroglucan, heparin, silk, 
chondroitin 6-sulfate, and polyhydroxyalkanoates [73]. 
Calcium Oxidized Cellulose 
Cellulose is a polysaccharide synthesized by grasses, woody plants, many forms of algae, 
fungi and some species of bacteria, namely Acetobacter xylinum. Bacterial cellulose is 
identical to plant cellulose in chemical structure, but it can be produced without contaminant 
molecules, such as lignin and hemicelluloses, and does not require intensive purification 
processes. In addition, it is remarkable for its mechanical strength and biocompatibility, so it 
has often been applied in tissue engineering [74].  
Cellulose in the human organism behaves as a non-degradable or very slowly degradable 
material.  An efficient method for inducing degradability of cellulose is its oxidation.  
Oxidized cellulose can be generated by various techniques and by various oxidizing 
agents, such as NaClO2, CCl4, nitrogene oxides or free nitroxyl radicals (TEMPO oxidation) 
[75], [76], [77].  
 
Figure 5: Oxidation proces of cellulose by NO2 gas [78]. 
Oxidized cellulose is degradable by hydrolysis, by mediated hydrolytic enzymes present 
in the serumsupplement of cell culture media in vitro, and in vivo, in macrophages [79]. 
Cellulose oxidation induces conversion of the glucose residues to glucuronic acid residues 
containing –COOH groups. The –COOH groups, which are polar and negatively charged, can 
be used for functionalizing the oxidized cellulose with various biomolecules [80]. 
Oxidized cellulose has been widely used as a wound healing material with excellent 
properties, such as high absorbability, antibacterial and antiviral properties, and non-toxic and 
antiadhesive effects [81]. Due to its ability to initiate or accelerate blood coagulation 
at the site where it is applied, oxidized cellulose has been used as a hemostatic material [82].  
Chitosan 
Chitosan is another biomaterial used in a variety of biomedical fields such as drug delivery 
carriers, surgical thread, and wound healing materials [83]. It is derived from chitin, is 
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an abundant polysaccharide that may be used to replace glycosaminoglycan [84].  Due to its 
many advantages for wound healing such as hemostasis, accelerating the tissue regeneration 
and the fibroblast synthesis of collagen, many applications of chitosan in skin tissue 
engineering have been reported [85]. In addition, chitosan can function as a bridge to increase 
the cross-linking efficiency of GA in the collagen-based scaffolds owing to the large number 
of amino groups in its molecular chain (Figure 6). Hence, one can expect that less GA could 
be used in the presence of chitosan and the potential cytotoxicity of GA might be decreased 
[86]. 
 
Figure 6: Schematic presentation of collagen cross-linked with glutaraldehyde in the presence 
of chitosan [86]. 
Chitin/Chitosan-Glucan Complex 
Fungal mycelial wastes from biotechnological plants can become free and rich alternative 
sources of chitin/chitosan materials, beside the traditional industrial source – shellfish waste 
materials. Moreover, the fungal chitosans can have unique properties compared with those 
derived from Crustacea. It have been tested possibilities of production and some applications 
of chitin-glucan complex and chitosan from industrial waste mycelia of Aspergillus niger 
from a citric acid production plant and Penicillium oxalicum from production of a red 
anthraquinone dye in Czech Republic. The alkali-insoluble cell-wall residue of the mycelia 
consists mainly of chitosan, chitin and ß-glucans, with a significant preponderance of (1→3)-
ß-D-glucan. Chitin is thought to be present as microfibrils physically embedded in the ß-
glucan matrix. The formation of the chitin/chitosan–glucan complex chains results in a rigid 
cross-linked network in the cell wall and causes a considerable problem for the extraction 
of intact chitosan and glucan [87]. 
2.6.2 Synthetic Polymers 
Synthetic polymers are man-made polymers, which have the advantages over the use 
of natural origin polymers as they are more flexible, more predictable and processable into 
different size and shapes and hove no immunogenicity [53]. The physical and chemical 
properties of a polymer can be easily modified and the mechanical and degradation 
characteristics can be altered by their chemical composition of the macromolecule. 
The functional groups and side chains of these polymers can be incorporated, i.e. the synthetic 
polymers can be selfcross-linked or cross-linked with peptides or other bioactive molecules. 
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Additionally, synthetic polymers are generally degraded by simple hydrolysis that is desirable 
as the degradation rate does not have variations from host to host, unless there are 
inflammations and implant degradation etc. to affect the local pH variations [72]. 
Synthetic polymers are largely divided into two categories: biodegradable and 
nonbiodegradeable. 
Biodegradable polymers are polyglycolide (PGA), polylactide (PLA) and its copolymer 
poly(lactide-co-glycolide), polycaprolactone (PCL), polyethylene glycol (PEG), 
polyphosphazene, polyanhydride, poly(propylene fumarate), polycyanoacrylate, 
polycaprolactone, polydioxanone, and polyurethanes.  
Nonbiodegradeable polymers include polyvinyl alcohol, polyhydroxyethymethacrylate, 
and poly(N-isopropylacrylamide).  
2.6.3 Bioceramics 
Melting inorganic raw materials to create an amorphous or crystalline solid body is known 
as bioceramics, and these porous final products are used mainly for scaffolds. 
Ceramic scaffolds are typically characterized by high mechanical stiffness (Young‘s 
modulus), very low elasticity, and a hard brittle surface. Ceramics are known to enhance 
osteoblast differentiation and proliferation [88], [89]. 
Bioceramics classified as (i) nonresorbable (relatively inert), for example alumina, 
zirconia, and silicon nitride; and (ii) bioactive or surface active (semi-inert), for example glass 
ceramics such as dense hydroxyapatites [9CaO·Ca(OH)2·3P2O5], and biodegradable 
or resorbable (noninert) such as calcium phosphates, aluminium calcium phosphates, 
coralline, tricalcium phosphates (3CaO·P2O5), zinc calcium phosphorus oxides, zinc sulphate 
calcium phosphates, ferric calcium phosphorus oxides, and calcium aluminates [53]. 
Collagen-based scaffolds can be also strengthened by introducing a ceramic phase [90]. 
These scaffolds not only possess significantly increased mechanical properties while retaining 
the highly porous and interconnected pore structure [91], but also show improved 
permeability which benefits cell infiltration and subsequent vascularization. 
2.6.4 Biocomposites 
Because each of the individual biomaterial groups has specific advantages and 
disadvantages, so the use of composite scaffolds comprised of different phases is becoming 
increasingly common. Composite scaffolds consists of at least one phase which is not found 
naturally in the body and they all have associated problems with biocompatibility, 
biodegradability or both. A more typical approach is the use of collagen-based scaffolds, 
either alone or with an additional phase incorporated to enhance biological and/or mechanical 
properties [71]. 
Combinations of (1) synthetic–synthetic, (2) synthetic–natural and (3) natural–natural 
polymers have ability to tailor mechanical, degradation, and biological properties but 
compromise the ―best‖ qualities of individual polymers with properties of the overall 
scaffold [53]. 
2.7 Collagen 
Collagen had been defined as a family of proteins located in the extracellular matrix 
of connective tissue that provides a structural basis for the mechanical and biochemical 
properties of tissues and organs [92]. 
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Several distinct types of collagen had been identified, which collectively, represent about 
one third of the total protein of vertebrate animals. As a function of structure and 
supramolecular organization, they were grouped as fibril-forming (types I, II, III, V, XI), 
fibril-associated (types IX, XII, XIV), membrane (types IV, VII, VIII, X) or other specific 
function. The fibrilforming collagens are the major structural element of connective tissue, 
providing the scaffold that gives stability and integrity to tissues and organs [67]. 
2.7.1 Structure of Collagen 
The collagen molecule consists of three polypeptide subunits known as α-chains twined 
around one another as in a three-stranded rope. Each chain has an individual twist 
in the opposite direction. The principal feature that affects a helix formation is a high content 
of glycine and amino acid residues. The strands are held together primarily 
by hydrogen bonds between adjacent –CO and –NH groups and also by covalent bonds [93]. 
Currently, 29 distinct collagen types have been characterized and all display a typical triple 
helix structure [94] which vary in the length of the helix and the nature and size 
of the nonhelical portions. Type I collagen is predominant in higher order animals especially 
in the skin, tendon, and bone where extreme forces are transmitted, and also has the advantage 
of possessing lower antigenic and hypoallergenic properties, therefore it is used as standard 
in the field of tissue-engineering. 
It is a compound of three chains, two of which are identical, termed α1(I), and one α2(I) 
chain with different amino acid composition or it can rarely represent a trimer built of three 
α1(I) chains. The basic collagen molecule contains three polypeptide α-chains, each 
consisting of more than one thousand amino acids [95]. Glycine has the smallest side group 
and its presence is essential at every third amino acid position in order to allow for a tight 
packaging of the three α-chains in the tropocollagen molecule and the X and Y positions are 
mostly filled by proline and 4-hydroxyproline (Figure 7a) [94], [96].  
 
 
Figure 7: Chemical structure of collagen type I. (a) Primary amino acid sequence, (b) secondary 
left handed helix and tertiary right handed triple-helix and (c) staggered quarternary structure [96]. 
Collagen also contains the unusual amino acid hydroxylysine. Formation of hydroxylysyl 
residues allows the attachment of sugar components, an unalterable requirement 
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for the collagen molecule to form a triple-helical structure. Both imino acids stabilize 
the triple helix. Due to their alicyclic nature, they stiffen the α-chain and form hydrogen-
bonds limiting rotation [97]. 
The unique physiological and biomaterial characteristics of collagen compared with most 
synthetic polymers derive from the structural complexity of the collagen molecule. There are 
observed the various levels of order in collagen. [98] The tertiary structure refers 
to the fundamental unit originally known as tropocollagen: three polypeptide chains 
intertwined to form a right-handed triple-helix with a pitch of approximately 8.6 nm.  
The rod-shaped triplehelix has an average molecular weight of approximately 300 kDa, 
a length of 300 nm with a diameter of 1.5 nm (Figure 7) [99]. 
There are regions of  9–26 amino acids at the amino and carboxyl terminal chain ends 
of the molecule that are not incorporated into the helical structure. These non-helical regions 
are denoted as telopeptides. On the fourth level of order, the triple-helical molecules associate 
of individual triple helices longitudinally and bilaterally into fibrils with distinct periodicity.  
The collagen molecules aggregate through fibrillogenesis into microfibrils consisting 
of four to eight collagen molecules and further into fibrils. Those fibrils reach from 10 
to 500 nm in diameter depending on tissue type and stage of development [99]. 
 
Figure 8: Overview of the collagen triple helix. (a) First high-resolution crystal structure 
of a collagen triple helix. (b) View down the axis of a (ProProGly) triple helix with the three strands 
depicted in space-filling, ball-and-stick, and ribbon representation. (c) Ball-and-stick image 
of a segment of collagen triple helix, highlighting the ladder of inter strand hydrogen bonds. 
(d) Stagger of the three strands in the segment in panel c [100]. 
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Collagen pro-α chain is synthesized from a unique mRNA within the rough endoplasmic 
reticulum and is then transferred to the Golgi apparatus of the cell. During this transfer, some 
prolines and lysines residues are hydroxylated by the lysyl oxydase enzyme. Specific lysines 
are glycosylated and then pro-α-chains self-assemble into procollagen prior to their 
encapsulation in excretory vesicles. Following their passage through the plasma membrane, 
the propeptides are cleaved outside the cell to allow for the auto-polymerisation 
by telopeptides. This step marks the initiation of tropocollagen self-assembly into fibril and 
the agglomeration of fibril into collagen fibers. Fibril-forming collagens are the most 
commonly used in the production of collagen-based biomaterials [101]. 
2.7.2 Physical and Chemical Propetries 
2.7.2.1 Natural Crosslinks 
Mechanical and chemical stability derives from intra- and intermolecular crosslinks. 
Initially, the formation of crosslinks is mediated by lysyl oxidase during fibril 
formation [102]. 
The enzymatic activity is limited to the non-helical telopeptide regions and leads 
to the conversion of selective lysyl and hydroxylysyl residues to the corresponding aldehydes 
allysine and hydroxyallysine (Figure 9). While the fibrils associate, the aldehydes can 
spontaneously react. Intramolecular crosslinks form between two α-chains in the non-helical 
section of the same molecule by aldol condensation of two aldehydes [102], [103]. 
Intermolecular crosslinks occur between the telopeptide region of one collagen molecule and 
the helical region of a quarterly staggered, adjacent molecule. These bridges between two 
different tropocollagen molecules result from aldimine formation (non-, mono- 
or dihydroxylated dehydrolysinonorleucine (D-HLNL)) between aldehyde residues and ε-
amino groups presented by lysine and hydroxylysine (Figure 9). The interchain bifunctional 
crosslinks are still reactive and continue to form polyfunctional crosslinks through multiple 
condensations with histidine, lysine, or hydroxylysine residues [104]. Besides the formation 
of enzymatic crosslinks there is a group of crosslinks derived from glycated lysine and 
hydroxylysine residues which occur more adventitiously [103]. Hence, through specific self-
aggregation and crosslinking, collagen can form fibers of unusual strength and stability. 
The degree of crosslinking increases with age and stress [105] and consequently changes 
the properties of collagen material. 
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Figure 9: Chemical structures of natural collagen crosslinks. (a) Oxidation of lysine and 
hydroxylysine via lysyloxidase, (b) intramolecular aldol condensation type crosslink, (c) 
intermolecular aldimine (Schiffs' base) type crosslink (R1, R2=H, OH: dehydrolysinonorleucine, 
dehydrohydroxylysinonorleucine, dehydrodihydroxylysinonorleucine (may undergo Amadori 
rearrangement to from ketoamine), (d) condensation of aldol condensation type crosslink with 
hydroxyproline (can further condensate with lysyl residue to form histidinohydroxymerodesmosine) 
and (e) hydroxypyridinium type crosslink [96]. 
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2.7.2.2 Degradation 
Collagen is particularly resistant to attacks by neutral proteases. At neutral pH only 
specific collagenases cleave the native helix at a position, about threequarters of the way from 
the N-terminus [106].  Fibrils as aggregates of collagen molecules are degraded starting from 
the exterior.  
Administration of exogenous collagen activates a complex cellular response which 
depends on the type of collagen material.  Collagen degradation by all these cell types can 
occur either after phagocytosis of partially cleaved fibers or by extracellular proteases acting 
at either neutral or acid pH. Activation of macrophages has been shown to cause a pH 
decrease in the micro-environment of collagen implants to below pH 5 [107]. Together with 
the excretion of cathepsin from macrophages and neutrophils [108] this creates an acidic 
pathway for collagen breakdown. 
In vitro degradation is usually simulated by incubation with bacterial collagenase, 
cathepsin, pepsin or trypsin [109]. 
2.7.2.3 Antigenicity and Immunogenicity 
Selective removal of the non-helical component from the collagen molecule suppresses its 
antigenicity [110]. Additional chemical crosslinking, e. g. with glutaraldehyde reduces 
the antigenicity but does not eliminate it completely [111]. Thus, the immunogenic response 
depends on the collagen source as well as the test technique and the species used for animal 
experiments [112]. Despite theoretical concerns animal collagen in the form of sutures, 
hemostatic agents, and injectable collagen is considered safe [113] and only mildly antigenic 
[114], making it suitable for use as an implantable and injectable biomaterial. 
2.7.2.4 Solubility for Isolation and Purification of Collagen 
The major impediment to dissolution of collagen type I from tissue is the presence 
of covalent crosslinks between molecules. Collagen is insoluble in organic solvents. 
Watersoluble collagen represents only a small fraction of total collagen. The nature 
of the crosslinks prevalent in different tissues determines the particular solvent to be used and 
the corresponding yields. 
The most commonly used solvents are neutral salt solution (0.15–2 M NaCl) or dilute 
acetic acid [115].   
Dilute acidic solvents, e.g. 0.5 M acetic acid, citrate buffer, or hydrochloric acid pH 2–3 
are more efficient than neutral salt solutions. The intermolecular crosslinks of the aldimine 
type are dissociated by the dilute acids and the repulsive repelling charges on the triple-
helices lead to swelling of fibrillar structures [116]. 
It is possible to solubilize approximately 2 % of the tissue collagen with dilute salt or acid 
solutions. These collagen molecules can be reconstituted into large fibrils with similar 
properties as native fibrils by adjusting the pH or temperature of the solution [109]. 
 The remaining 98 % is referred to as insoluble collagen although this dominant collagen 
material is not absolutely insoluble and can be further disintegrated without major damage 
to the triple-helical structures. The two most common approaches are the use of strong alkali 
or enzymes to cleave additional crosslinks and suspend or dissolve at first acid-insoluble 
structures. 
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Instead of disintegration and transfer into soluble material, extensively crosslinked 
collagen can be dispersed as opalescent, fine fibrillar suspensions by the use of mild 
denaturation agents and mechanical fragmentation usuallyat an acidic pH. 
In additional steps collagen material can be subjected to chemical modifications such as 
succinylation [117],  acetylation [118], methylation [119] or attachment to other 
polymers [120]. 
2.7.3 Crosslinking 
In common with all natural polymers, one major problem with using collagen as the main 
constituent of a scaffold for orthopedic tissue engineering is that it has relatively poor 
mechanical properties. Natural crosslinking gives high tensile strength and proteolytic 
resistance to collagen. Dissociation of crosslinks can lack sufficient strength and may 
disintegrate upon handling or collapse under the pressure from. Therefore, it is often 
necessary to confer mechanical firmness and collagenase resistance by introduction 
of exogeneous crosslinking into the molecular structure [121], [122]. 
Cross-linking of the collagen-based scaffolds is an effective method to modify 
the biodegrading rate (enzymatic resistence) and to optimize the mechanical property 
for implantation purposes. The principle of a cross-linking reaction relies on the modification 
of amine and carboxyl groups within the collagen molecules, to allow the formation 
of covalent bonds. Several methods have been developed to cross-link collagen scaffolds. 
These polymerization techniques are distributed among three types: physical, chemical and 
enzymatic crosslinking. 
An alternative to covalent bond crosslinking is to promote the formation of ionic bonds 
between collagen molecules. This can be achieved by polycationic molecules such as 
chitosan, which create ionic bonds between its numerous amine groups and the carboxyl 
groups of collagen. These bonds are strong enough to stabilize the biomaterial structure and 
form a strong mechanical strength [123], [124]. The major advantage of this technique is 
to prepare the biomaterial in a one step process, where chitosan is mixed with collagen before 
freeze-drying, avoiding the need of further washing steps since chitosan is not toxic [125]. 
Enzymatic crosslinking agents like transglutaminase can be used to enhance tensile 
strength and enzymatic resistance of collagen-based biomaterial [126], [127], [128]. 
The major advantage with the approach of using a biologic polymerization technique is that 
no chemical residues or by-products remain in the scaffold structure, and therefore eliminate 
the risk of inducing cytotoxic effects.  
A plethora of biomolecules can also be added to collagen solution to produce collagen-
based biomaterials. These biomolecules, typically GAG, elastin and chitosan are added 
to the compound to potentially enhance the mechanical strength and to modulate cellular 
functions such as migration, proliferation and differentiation [129],  [130], [131], [132], [133], 
[134], [135]. 
 
2.7.3.1 Physical Treatment 
Alternative physical methods are pursued, including dry heat, exposure to ultraviolet    
or γ-irradiation, because chemical crosslinking agents is the potential toxic effect of residual 
molecules and/or compounds formed during in vivo degradation [136]. Collagen becomes 
partially denatured by these physical treatments [137]. In order to keep degradation 
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of the triple-helices to a minimum it is crucial for dehydrotermal (DHT) treatment to reduce 
the water content via vacuum as thoroughly as possible prior to heating [138]. Severe 
dehydration itself already induces amide formation and esterification between carboxy and 
free amino and hydroxyl groups, respectively [139], [140]. The combination of degradation 
and crosslinking allows non-specific enzymes to attack and solubilize fragments 
of the crosslinked material. Formation of crosslinks during UV-irradiation is thought to be 
initiated by free radicals formed on aromatic amino acid residues [137] which indicates 
a rather limited maximum degree of crosslinking due to the small number of tyrosine and 
phenylalanine residues in collagen.  
2.7.3.2 Syntetic Crosslinkers 
Due to the large number of functional side groups it contains, collagen readily undergoes 
chemical crosslinking. This is usually performed using bifunctional reagents 
as glutaraldehyde (GTA), dialdehydes and diisocyanates, as well as carbodiimides, 
diepoxides, polyepoxy compounds, formaldehyde and acyl azide methods [141], [142], [143], 
[144].  
Using this agents it is possible to create a three-dimensional network that results 
in collagen scaffolds with enhanced mechanical properties. However, glutaraldehyde and  
1,6-hexamethylene diisocyanate have been found to be cytotoxic and as such carbodiimide 
or acyl azide methods have been introduced  [145], [146].  However, both methods have 
limited cross-linking ability due to their short length structure and inability 
to polymerise [147]. 
Carbodiimides 
Crosslinking with carbodiimides, especially 1-ethyl-3-(3-dimethylaminopropyl)-
carbodiimide (EDC) offers the main advantage over aldehydes, HDC, or epoxy compounds 
in that these carbodiimides only facilitate the formation of amide bonds between carboxylic 
and amino groups on the collagen molecules without becoming part of the actual linkage. 
Thus, bifunctional crosslinking agents are obviated. Carbodiimides first couple to a carboxylic 
group to form o-isoacylurea structures. The resulting activated intermediate is attacked 
by a nucleophilic primary amino group to form an amide crosslink and the isoureaderivative 
of the applied carbodiimide is eliminated and can be washed out [148], [149]. 
The susceptibility of carbodiimide crosslinked material to enzymatic degradation can be 
controlled by varying the degree of cross-linking via the reaction conditions [150].  
Nowadays it si most commonly used N-ethyl-N′-[3–dimethylaminopropyl]carbodiimide/ 
N-hydroxy succinimide (EDC/NHS) as a non-toxic cross-linker which crosslinks without 
incorporation of the crosslinking reagent [82]. 1-Ethyl-3-(3-dimethyl aminopropyl) 
carbodiimide (EDC) or acylazide were used to generate peptide-like bonds in biomaterials 
[151]. Use of EDC and N-hydroxysuccinimide (NHS) to crosslink collagen seems to yield 
biomaterials with good biocompatibility, higher cellular differentiation potential and with 
increased resistance against enzymatic degradation [152]. 
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Figure 10: Schematic reaction of collagen with EDC/NHS. 
2.7.3.3 Natural Cross-linking Agents 
The syntetic substances for cross-linking are tried to be replaced by crosslinking agent able 
to form stable and biocompatible crosslinked products, without added cytotoxicity problems. 
This is the reason of the increasing demand for natural crosslinking agents for medical 
applications [153]. Natural crosslinkers have high biological activity and can significantly 
improve collagens properties while preserving its triple-helical structure [154]. 
Recent data demonstrate that plant extracts not only optimally stabilise collagen scaffolds 
and bring about mechanical properties similar to native extracellular matrix assemblies, but 
also do not compromise cell attachment, proliferation and growth [155], [156], [157], [158], 
[159], [160], [161], [162], [163]. 
Genipin is a natural cross-linking agent found in plants, which has been shown to be quite 
efficient in protein cross-linking [164]. Using citric acid as a crosslinked molecule will avoid 
inducing toxic substances. CA can easily react with the amidogen on the collagen chain and 
form cross-links to enhance the mechanical strength [165]. Stabilisation using M. rubra could 
be a valuable alternative to aldehyde approaches for the construction of three-dimensional 
scaffolds that would imitate native extracellular matrix assemblies [166]. The interactions 
between protein and polyphenol can involve hydrogen bond, covalent linkage, ionic and 
hydrophobic bonding. The hydrogen bond interaction is mainly responsible 
for the stabilization of collagen by procyanidin. The procyanidin treatment does not destroy 
the triple helix conformation of collagen, but induces the aggregation of collagen microfibrils 
[167]. 
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2.8 Scaffold Fabrication Techniques 
In the last decade, various fabrication methods for construction of three-dimensional 
biomimetic scaffolds, including electrospinning [168], [169], [170], phase-separation [171], 
[172], freeze drying [173], [174] and self-assembly [175], [176] have been developed 
for tissue engineering and regenerative medicine. These scaffolds can mimic the architecture 
of the native extracellular matrix at the nanoscale level (eg, hierarchical architecture formed 
with nanofibers and nanopores), which provides the initial space for regeneration of new 
tissue [177].  
In addition, surface modification methods (eg, plasma exposure) used for nanostructured 
scaffolds can introduce functional groups (e. g. Arg-Gly-Asp peptide) onto the surface 
of the scaffolds, which directly and significantly enhance cell attachment, migration, and 
proliferation.  
Traditional tissue engineering methods use a ―top-down‖ approach, in which cells are 
seeded onto a scaffold with biocompatible and biodegradable properties, and are expected 
to populate in the scaffold and create their own extracellular matrix. Despite several thin or 
avascular tissues, such as skin [178], bladder [179], and cartilage [180], having been 
engineered successfully via the top-down approach based on these biomimetic scaffolds 
in vitro, the fabrication of complex larger functional tissues (eg, liver and kidney) with high 
cell densities and high metabolic requirements still faces challenges. This is mainly because 
of the limited diffusion properties of biomimetic scaffolds [181].  
Tissue engineered constructs can also be fabricated by the assembly of smaller building 
blocks. This approach mimics much of the native biology that is often made from repeating 
functional units. For example, in the liver, the sinusoid is the repeating functional unit. 
Bottom-up approaches can be used to generate functional units that can be assembled 
in a modular approach to generate larger scaffolds [182]. Fabrication of tissue building blocks 
can be achieved via multiple approaches, including fabrication of cell-encapsulating 
microscale hydrogels (microgels), self-assembled cell aggregation, generation of cell sheets, 
and direct printing of cells [183], [184], [185] (Figure 11). These microscale building blocks 
can be successfully assembled into complex tissue constructs, with control over features such 
as the shape and composition of individual blocks [186], [187]. 
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Figure 11: Schematic of “top-down” and “bottom-up” approaches for tissue engineering. 
(A) In the top-down approach, cells are seeded on a biocompatible and biodegradable scaffold and 
are expected to populate in the scaffold and create their own extracellular matrix. (B) In the bottom-
up approach, various methods are utilized for generating tissue building blocks and these units can be 
engineered into large tissue constructs via multiple assembling methods [188]. 
2.8.1 Conventional Scaffold Fabrication Techniques 
Several techniques have been developed to process synthetic and natural scaffold materials 
into porous structures. These conventional scaffold fabrication techniques are defined herein 
as processes that create scaffolds having a continuous, uninterrupted pore structure which 
lacks any long-range channelling microarchitecture. 
Conventional scaffold fabrication techniques include: 
 fiber bonding [189] and [190],  
 phase separation [191] and [192],  
 solvent casting/particulate leaching [193], [194], [195] and [196],  
 membrane lamination [197],  
 melt molding [198],  
 gas foaming/high pressure processing [199] and [200],  
 hydrocarbon templating [201],  
 freeze drying [202], [203],   
 combinations of these techniques (e. g., gas foaming/ particulate leaching [204], etc). 
Although conventionally produced scaffolds hold great promise and have been applied 
to engineer a variety of tissues with varying success, most are limited by some forms of flaws, 
which restrict their scope of applications.  
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Table 2: Summarizes the advantages and limitations of these conventi onal techniques [205]. 
Technique Advantages Limitations 
Fiber bonding Easy process 
High porosity  
High surface area to volume ratio 
High processing temperature for non-
amorphous polymer 
Limit range of polymers 
Lack of mechanical strength 
Problems with residual solvent 
Lack of control over micro-architecture 
Phase separation Allows incorporation of bioactive 
agents  
Highly porous structures 
Lack of control over micro-architecture 
Problems with residual solvent 
Limited range of pore sizes 
Solvent casting and 
particulate leaching 
Highly porous structures 
Large range of pore sizes  
Independent control of porosity 
and pore size  
Crystallinity can be tailored 
Limited membrane thickness 
Lack of mechanical strength 
Problems with residual solvent 
Residual porogens 
Membrane lamination Macro shape control  
Independent control of porosity 
and pore size 
Lack of mechanical strength 
Problems with residual solvent 
Tedious and time-consuming 
Limited interconnected pores 
Melt moulding Independent control of porosity 
and pore size  
Macro shape control 
High processing temperature for non-
amorphous polymer 
Residual porogens 
Polymer/ceramic fiber 
composite-foam 
Good compressive strength  
Independent control of porosity 
and pore size 
Problems with residual solvent 
Residual porogens 
High-pressure processing Organic solvent free  
Allows incorporation of bioactive 
agents 
Nonporous external surface 
Closed pore structure 
High-pressure processing 
and 
particulate leaching 
Organic solvent free  
Allows incorporation of bioactive 
agents 
Highly porous structures 
Large range of pore sizes 
Independent control of porosity 
and pore size 
Limited interconnected pores 
Lack of mechanical strength 
Residual porogens 
Freeze drying Highly porous structures  
High pore interconnectivity 
Limited to small pore sizes 
Hydrocarbon templating No thickness limitation  
Independent control of porosity 
and pore size 
Problems with residual solvent 
Residual porogens 
2.8.2 Solid Freeform Fabrication Techniques 
Solid freeform fabrication (SFF) techniques are computerized fabrication techniques that 
can rapidly produce highly complex three-dimensional physical objects using data generated 
by computer-aidede design (CAD) systems, computer-based medical imaging modalities, 
digitizers and other data makers [206]. Unlike conventional computerized machining 
processes which involve the removal of materials from a stock, SFF techniques uses 
the underlying concept of layered manufacturing [206], [207] whereby three-dimensional 
objects are fabricated with layer-by-layer building via the processing of solid sheet, liquid 
or powder material stocks.  
Solid freeform fabrication (SFF) may produce scaffolds with customised external shape 
and predefined and reproducible internal morphology, which not only can control pore size, 
porosity an pore distribution, but can also make structures to increase the mass transport 
of oxygen and nutrients throughout the scaffold.  
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The flexibility and outstanding manufacturing capabilities of SFF have been employed 
for biomedical applications ranging from the production of scale replicas of human bones 
[208] and body organs [209] to advanced customized drug delivery devices [210] and other 
areas of medical sciences including anthropology [211], palaeontology [212] and medical 
forensics [213].  
SFF include: 
 three dimensional printing (3DP), 
 stereolithography (SLA), 
 fused deposition modelling (FDM), 
 selective laser sintering (SLS), 
 3D plotter, 
 phase-change jet printing [214]. 
Table 3: Summarizes the capabilities and limitaions of the three solid free-form fabrication 
techniques [205]. 
Technique Build resolution, [mm] Advantages Limitations 
3D-P 0,100 ± 0,020 
Achievable pore size = 
45–100 μm 
Easy process  
High porosity 
High surface area to volume ratio  
Complete pore interconnectivity 
Macro shape control 
Independent control of porosity 
and pore size 
Wide range of materials 
Use of toxic organic solvents 
Lack of mechanical strength 
Limited to small pore sizes 
FDM 0,050 ± 0,127 
Achievable pore size = 
250–1000 μm 
High porosity  
High surface area to volume ratio 
Complete pore interconnectivity  
Macro shape control  
Independent control of porosity 
and pore size 
Good compressive strengths 
Solvent free 
High processing temperatures 
Limited material range 
Inconsistent pore opening 
in x-,y- and z-directions 
Pore occlusion at boundaries 
Requires support structures 
for irregular shapes 
SLS 0,076 ± 0,250 
Achievable pore size = 
45–100 μm 
High porosity  
High surface area to volume ratio  
Complete pore interconnectivity 
Macro shape control 
Independent control of porosity 
and pore size 
Good compressive strengths 
Wide range of materials 
Solvent free 
High processing temperatures 
Limited to small pore sizes 
2.8.3 Collagen Scaffold the Most Used Fabrication Techniques 
Many extracellular proteins, including collagen, have a nanoscale fibrous structure (50–
500 nm in diameter) in vivo which has been found to enhance cell attachment, proliferation, 
and differentiation [215], [216]. Nanofibrous biomimetic scaffolds consist of biodegradable 
polymer nanofibers, which can be fabricated by several methods, including electrospinning, 
phase-separation, and self-assembly, and can mimic the nanofibrillar structure 
of the extracellular matrix in vivo (Figure 12). In Table 4 are summarized parameters 
of mentioned methods. 
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Figure 12: Schematic of current techniques (a)  phase separation, (b) self-assembly, and 
(c) electrospinning to create fibrillar structures in synthetic scaffolds [217]. 
Table 4: Different methods for fabricating three-dimensional nanostructured scaffolds [188]. 
Method Polymer 
Diameter 
of fiber [nm] 
Porosity 
Cell 
viability 
Material types/ 
commercially 
available 
Applications 
for TE 
Electro-
spinning 
PLLA 
PLGA 
PGA/PLLA 
Collagen/PCL 
Chitosan/PCL 
Silk/HAP 
400–1100 
 
80%–95% 
 
<80% 
 
30/ 
available 
Skin 
Cartilage 
 
Vascular 
Nerve 
Bone 
Phase-
separation 
PLLA/HAP 
PLGA 
Chitosan 
50–500 
 
60%–98% 
 
<98% 
 
15–20/ 
available 
Bone 
Freeze-
drying 
Chitosa/PLLA 
Collagen/GAG 
Gelatin-PHEMA 
50–450 
30%–80% 
 
<90% 
 
15/ 
available 
Tendon 
Bone/tendon 
Skin 
Self-
assembly 
Peptide 
5–300 
 
80%–90% 
 
60%–95% 
 
5–10/ 
not known 
Cartilage 
Here, we focus only on the method we use for fabrication porous collagen sponges – phase 
separation, especially freeze-drying fabrication method. 
2.8.3.1 Phase Separation 
The phase separation process can be induced thermally or by a nonsolvent and was 
developed for the fabrication of 3D porous scaffolds [174], [218], [219]. Induction 
of the phase separation process using a nonsolvent commonly results in scaffolds with 
a heterogeneous pore structure which is not suitable for fabrication of tissue engineering 
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scaffolds, which generally need a uniform pore structure [220]. The thermally induced phase 
separation process takes place when a homogeneous polymer solution becomes 
thermodynamically unstable under certain temperature conditions and tends to separate into 
a multiphase system domains, comprising a polymer-lean phase (with a low polymer 
concentration) and a polymer-rich phase (with a high polymer concentration) [221], [222]. 
Subsequently, the polymer-rich phase solidifies to form a matrix while the polymer-lean 
phase turns into pores as a result of solvent removal.  Thermally induced phase separation can 
be divided into solid-liquid phase separation and liquid-liquid phase separation.  
The solid-liquid phase separation proces, also called emulsion freeze drying, is used 
to induce solvent crystallization from a polymer solution by lowering the temperature, which 
leads to formation of pores after removal of solvent crystals.  
Freeze-drying has emerged as a drying process for converting solutions of labile materials 
into solids of sufficient stability for distribution and storage in applications such as food 
science, pharmaceuticals, and enzyme stabilization [223], [224], [225]. Freeze-drying 
involves three major steps: the solution is frozen at a low temperature (−70 °C to −80 °C); 
the frozen sample is located in a chamber in which the pressure is lowered (to a few millibars) 
through a partial vacuum, known as the primary drying process, in which ice in the material is 
removed by direct sublimation; and most of the unfrozen water in the material is removed 
by desorption in a secondary drying process.  
Porosity and pore diameter in porous scaffolds prepared using the freeze-drying method 
can be regulated by the freeze-drying pressure [219], (Figure 13). Although there are several 
advantages of the freeze-drying method, including use of water and ice crystals instead 
of an organic solvent in the scaffold fabrication process, which is more suitable 
for biomedical applications, it is still a big challenge to engineer scaffolds with hierarchical 
structures (e.g. vascularized systems) using this approach. 
 
 
Figure 13: The schematic diagram of solid-liquid phase separation – freeze-drying technique 
[226]. 
In the liquid-liquid phase separation process, polymer solutions with an upper critical 
temperature form a bicontinuous structure (both polymer-lean phase and polymer-rich 
phase) [4], [227].  
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Various synthetic polymeric nanofibers have been fabricated using phase separation 
methods for tissue engineering applications [171], [172], [192], [228].  Several natural 
polymers have been fabricated into three-dimensional porous scaffolds, for instance, chitosan 
scaffolds with nanofibrous or microfibrous structures  prepared by solid-liquid phase 
separation.  
The porosity and fiber size of the scaffolds can be regulated by several methods, including 
phase separation temperature and polymer concentration [229].  
Phase separation holds great potential for fabrication of three-dimensional nanofibrous 
scaffolds with uniform pore structures through dual or multiple phase separation processes. 
In addition, phase separation can engineer three-dimensional shapes via several techniques, 
including solid free-form fabrication, rapid prototyping, and computer-assisted design and 
manufacture. However, limitations such as limited material selection and inadequate 
resolution still exist. 
2.9 Collagen-Based Scaffolds for Tissue Engineering and Their Application 
The material of scaffolds for tissue engineering can be any biomaterial that mimics one 
or multiple characteristics of the natural ECM [230], but is expected to function as a scaffold 
to replace natural collagen-based ECM. Much research has been reported on collagen, its 
denatured forms or collagen-based materials as biomaterials for scaffold fabrication in tissue 
engineering [231], [232], [233], [234], [235], [236]. 
2.9.1 Pure Collagen Scaffold 
Collagen type I, II and III could form collagen fibers that are similar to or even fully 
reproduced the structural and biological properties of the natural collagen ECM under 
optimizing conditions. By electrospinning, collagen type I produced fibers exhibiting 
the 67 nm D-repeat banding pattern, which is a characteristic of native collagen [237].Using 
lyophilization can be determined the collagen concentration in solutions which determines 
the mechanical properties of the scaffold [238]. Proper concentration could be chosen 
according to the implant position of the scaffold. 
Despite the excellent biological properties of the pure collagen scaffold, it presents poor 
mechanical properties and structural stability. Physical treatment or chemical agents can be 
used to achieve intermolecular cross-linking of collagen, thus modifying the properties 
of the collagen scaffold.  
2.9.2 Collagen/Natural Polymer Blend Scaffold 
Cross-linking strategies of the pure collagen scaffold enhance the mechanical and 
structural properties, but may introduce negative effects on cellular response in vivo. Hence, 
a mixture of natural or synthetic polymers can be used to overcome the limitations 
of the monocomponent system. Natural polymers (such as chitosan, silk fibroin, hyaluronic 
acid, alginate, etc.) have been widely used in tissue engineering due to their similar features 
to native ECM [239]. 
2.9.3 Collagen/Synthetic Polymer Blend Scaffold 
Blending of collagen with synthetic polymers also makes it possible for scaffolds 
to perform both with optimal mechanical and biological properties in specific engineering 
applications. In this case, the synthetic polymer undertakes mechanical support 
to the structure of scaffolds, while collagen on the surface and inside of the scaffolds provides 
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cell recognition signals, which is crucial for cell behaviors and development [240]. Scaffolds 
composed of collagen and synthetic polymers, such as poly (ε-caprolactone) (PCL), polylactic 
acid (PLA), poly(ethylene glycol) (PEG), polyglycolide (PGA), poly(lactide-co-glycolide) 
(PLGA) and polyvinyl alcohol (PVA), have been widely used for tissue engineering. 
2.9.4 Collagen/Inorganic Hybrid Scaffold 
Organic-inorganic composite materials have drawn much attention due to their ability 
to combine excellent properties of individual constituents. Hybridization can achieve tailor-
made performances (such as morphology, stiffness, degradation) and meet various 
requirements in tissue engineering [241], [242]. Several inorganic materials, such as 
hydroxyapatite (HA, Ca10(PO4)6(OH)2), silicate and β-tricalcium phosphate (β-TCP, 
Ca3(PO4)2), have been used in the construction of tissue engineering scaffolds. 
2.9.5 Collagen Scaffold Modified with Growth Factors 
Growth factors can regulate a variety of cellular processes; they are intercellular signaling 
molecules promoting cell migration, proliferation, differentiation and maturation depending 
on their type [243].  
Generally, there is an initial burst release of growth factors encapsulated in the scaffold, 
which is usually not effective and welcome. Hence, an appropriate loading method is crucial 
to the stable, sustainable and controllable release of growth factors on the scaffold. 
2.9.6 Applications of Collagen-Based Scaffolds in Tissue Engineering 
In this section, several typical applications of collagen-based scaffolds in tissue 
engineering will be introduced, respectively. 
2.9.6.1 Nerve Tissue 
Collagen-based biomaterials have been extensively studied as a promising nerve guide 
[244], [245], [246], [247]. Multiple compositions of collagen-based nerve conduits have 
recently been tested with positive results compared to clinically used autografts. Most 
collagen nerve guides are engineered from crosslinked collagen solution molded into tubular 
shape [248]. Pore orientation [249], [250], addition of neurotrophic factors [251], [252] and 
cell delivery [253], [254], [255] are currently being investigated in an attempt to enhanced 
nerve guides for clinical applications. Collagen-based biomaterials can also be used 
to develop innovative three-dimensional tissue-engineered nervous system models to promote 
3D axonal migration and myelination of sensory or motor neurons by Schwann cells through 
a connective tissue [256]. 
2.9.6.2 Bone/Cartilage Tissue 
Bone tissues are mainly composed of collagen type I and HA with a small amount 
of type V. Hence, collagens blended with nano-inorganic materials are more widely used 
to prepare scaffolds that mimic natural ECM of bone in bone repair. 
Cartilage defects cause joint pain and loss of mobility [257]. Chondrocytes show low rates 
of regeneration due to their non-mobility and the absence of progenitor cells and vascular 
networks in the tissue [258]. MSCs have been commonly employed as a main source 
of seeding cells in cartilage tissue engineering.  
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2.9.6.3 Tendon/Ligament Tissue 
Tendons and ligaments are fibrous connective tissues, with collagen comprising 70 % 
to 80 % of their dry weight [259]. Both tendon and ligament have weak spontaneous 
regeneration ability and never totally recover from full-thickness lesions. The substantial 
donor site morbidity limits autograft applications for injured tissue and encourages the search 
for alternative solutions. Collagen scaffold provides an excellent way for tendon/ligament 
repair and regeneration. 
2.9.6.4 Vascular Disseases 
Two main problems arise in the domain of vascular diseases: cardiovascular malfunction 
and venous or arterial pathologies such as atherosclerosis. In the case of heart diseases, tissue 
engineering solutions rely principally on acellular matrix colonization and implantation due 
to the complex structural architecture of the heart like heart valves [260], [261]. 
Vascular grafts may induce immediate thrombus after implantation due to their lack 
of healthy endothelium. Vascular endothelialization can reduce thrombosis, inhibit excessive 
hyperplasia of intima and significantly improve the long-term patency rate of artificial blood 
vessels.  
Considering the typical requirement of autologous cells, whose amplification in vitro is 
time consuming, cell-free vascular grafts have gained much attention.  
Combining the cell-free vascular graft with endogenous ECs represents a great progress 
in vascular tissue engineering. Future research directions may be focused on the development 
of vascular material and immobilization of growth factor. 
2.9.6.5 Skin and Cornea 
Skin and cornea share a similar tissue structure: dermis and stroma both being connective 
tissues; epidermis and cornea being stratified epithelia. Collagen-based wound dressings have 
been applied for decades for burn coverage applications and ulcer treatment [262], [263]. 
Highly sophisticated and innovative tissue-engineered skin models have been developed with 
melanocytes [264], a capillarylike network [265], dendritic cells [266], sensory innervation 
[133], [256], adipose tissue [267], and tissue reproducing psoriatic or sclerotic phenotypes 
[268], [269]. 
Mesenchymal stem cell delivery to the wound bed in collagen-based biomaterial is 
a growing topic in wound healing [267], [270], [271]. The combination of collagenous 
biomaterials and stem cells could also be a valuable strategy to treat corneal defects. 
In the last decade, collagen scaffolds have been intensively studied for the delivery of limbal 
epithelial stem cells to damaged cornea [272], [273], [274], [275], [276], [277]. Advances 
in collagen-based corneal scaffolds also include the utilization of recombinant human 
collagen [276], [278], [279], [280], [281], the secretion of collagen by the fibroblasts 
themselves (self-assembled fibroblasts sheets) [282] and surface modification to reduce 
extensive endothelialization [283]. 
Many organic/inorganic materials can be used to strengthen the properties of collagen 
scaffolds in scientific research, but the materials approved by the U.S. Food and Drug 
Administration (FDA) for clinical applications are limited. The FDA has approved only 
collagen, hyaluronic acid, PLLA, HA and non-biodegradable polymethylmethacrylate 
(PMMA) beads used as dermal fillers since July 2015 [284]. 
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2.9.6.6 Urogenital System 
The use of collagen-based biomaterials in the domain of urogenital diseases and 
dysfunctions rely principally on acellular ECM from either small intestinal submucosa (SIS) 
or bladder submucosa (BSM) [285], [286]. More recent surgical procedures aiming to solve 
genitourinary disorders use acellular collagen scaffolds in bladder augmentation [287], [288], 
[289] and urethral stricture [291], [292], [293].  
Collagen-composite scaffolds populated with the patient‘s own urothelial and muscle cells 
or self-assembled fibroblast sheets are also a promising strategy for bladder augmentation 
[294], [295], [296]. Vesico-urethral reflux and incontinence are other defects of the urogenital 
system which can also be solved using injection of collagen biomaterials [297], [298], [299]. 
2.9.6.7 Dermal Filler, Wound Dressing and Delivery Systems 
FDA approved dermal filler commonly used in facial rejuvenation or reconstructive 
surgery is using collagen from three distinct sources: Bovine Zyderm®, porcine Evolence™, 
human CosmoDerm® and Cymetra® [300], [301]. Although other collagen-based 
biomaterials are available for this purpose [302], these products can be useful for medical 
office-based interventions.  
Wound dressings that are also delivery systems represent an interesting application 
for collagenbased applications.  
The delivery properties of collagen-based biomaterials also display great potential for ulcer 
treatment [250]; abdominal wall defect reconstruction [303], [304], [305]; implants delivering 
antibiotics [306], [307], [308], [309]; gene therapy delivered by collagen matrix [310].  
Collagen scaffolds have also shown to accurately deliver cells, proteins, drugs and nucleic 
acids on a predictable and long-term basis [311], [312], [313], [314]. The biodegradability 
of collagen and its low immunogenicity make it a substrate of choice for internal and topical 
pharmacogenomical applications. 
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3 EXPERIMENTAL PART 
Purpose of experimental part was to prepare 3D porous collagen scaffolds by freeze-drying 
and their modification with bioactive compounds, as well as observe the influence 
of biologically active additives, crosslinking agents, and enrichment with growth factors 
on the properties of the prepared scaffolds and their bioactivity in tissues of living organisms. 
For the characterization, morphological properties, structure, porosity, swelling stability, 
chemical composition and biological properties were observed.  
The experimental part is secret for the protection of intellektual property. 
3.1 Chemicals 
3.2 Equipments 
3.3 Preparation of Chitin/Chitosan-Glucan Complex 
3.4 Preparation of Samples 
3.4.1 Collagen Sponges 
3.4.2 Collagen Sponges with CaOC 
3.4.3 Collagen Sponges with Chitosan 
3.4.4 Collagen Sponges with Complex 
3.4.5 Crosslinking of Collagen Sponges with Carbodiimides 
3.4.6 Sponges Enriched with PRP 
3.5 Characterization of the samples 
3.5.1 Morphology and Porosity 
3.5.2 Swelling Ratio and Water Content 
3.5.3 Degradation  
3.5.4 Fourier Transformed-Infrared Spectroscopy 
3.5.5 Differential Scanning Calorimetry 
3.5.6 Biological Properties 
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4 RESULT AND DISCUSSION 
4.1.1 Morphology and Porosity 
4.1.2 Swelling Ratio and Water Content 
4.1.3 Degradation 
4.1.4 Fourier Transformed-Infrared Spectroscopy 
4.1.5 Differential Scanning Calorimetry 
4.1.6 Biological Properties 
41 
 
5 CONCLUSION 
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